Nference

nference is an agentic AI platform for healthcare research that serves as the intelligence layer for clinical research. The company partners with medical centers and healthcare systems to activate decades of real-world clinical data — much of it unstructured — captured in electronic medical records (EMRs), transforming it into powerful, research-ready solutions. nference enables scientists, clinicians, and life sciences organizations to discover and develop the next generation of personalized diagnostics and treatments for patients worldwide. Founded by Murali Aravamudan (CEO) and Venky Soundararajan, PhD (Chief Scientific Officer), nference is headquartered in Cambridge, MA, with additional offices in Bangalore, Toronto, and Rochester, MN.

At its core, nference believes the greatest opportunity to elevate human health lies in curating and synthesizing the world's biomedical data through multimodal AI. The platform connects healthcare partners through a federated AI network, optimizing clinical data management and enabling real-world data (RWD) to generate impactful insights. nference has established long-term partnerships with leading healthcare centers and life sciences companies, including collaborations with Valo Health, Avadel, and BeiGene.

Research-Ready Patient Data at Scale

• Radiology: Over 10 billion radiology images spanning multiple modalities including PET, CT, MRI, X-rays, and ultrasound.
• Pathology: More than 20 million digitized whole slide images linked to patient records.
• ECG: Over 12 million resting ECG raw waveforms and reports analyzed using advanced AI.
• Echo Videos: More than 100 million videos capturing echocardiograms to assess the structure and function of the heart.
• EHR Notes: Over 1.4 billion clinical notes documenting patient medical history, symptoms, treatment plans, and quality of care.
• Biomarkers: More than 30,000 unique clinical biomarkers extracted from unstructured data through AI.

Therapeutic Areas Supported

• Cardiology: Supports research enhancing clinical data analysis to improve patient outcomes, addressing cardiovascular diseases that affect approximately 48% of Americans over age 20.
• Oncology: Empowers researchers to expedite the discovery and development of effective cancer therapies, with cancer cases projected to surpass 35 million by 2025.
• Immunology: Enables leading-edge immunology clinical trials and supports research into drug efficacy, building on lessons from recent pandemic-era breakthroughs.
• Rare Diseases: Provides novel molecular data to help identify genomic changes across more than 7,000 known rare diseases affecting 300 million people worldwide.
• Neurology: Supports the development of newer, more effective therapies for neurological conditions affecting over 3 billion people globally.
• Infectious Diseases: Aids scientists in developing effective prevention and treatment strategies for infectious diseases affecting approximately 1 billion individuals worldwide.
• Nephrology: Leverages real-world data to help researchers improve diagnosis and potentially prevent acute kidney disease from progressing to chronic conditions, addressing an estimated 850 million people affected globally.

Products and Platform Capabilities

• nSights Platform: An AI-powered platform for clinical data analysis, patient cohort design, clinical journey exploration, data annotation for model development, anatomical computations, and advanced data science workbench capabilities.
• Design Patient Cohorts: Tools enabling researchers to define and build precise patient populations for clinical and translational research.
• Explore Patient Journey: Functionality to trace and analyze longitudinal patient pathways across care settings.
• Data Annotation for Model Development: Capabilities to label and structure multimodal clinical data for training AI and machine learning models.
• AI Platform for Anatomical Computations: Specialized AI tools for processing and analyzing anatomical imaging data.
• Advanced Data Science Workbench: A robust environment for data scientists to conduct sophisticated analyses on real-world clinical datasets.

Venture Creation and Spin-Outs

• Anumana: A venture created from the nference platform that harnesses industry-leading AI and translational science to decode the electrocardiogram as a deep predictive tool and biomarker of disease, empowering care providers to identify and help patients earlier.
• Pramana: A health technology company spun out of nference that enables seamless digital adoption by pathology labs and medical centers.

nference serves both life sciences organizations and health systems, offering solutions for clinical researchers, data scientists, and collaborative research partnerships. The platform's federated AI network and comprehensive multimodal data assets position nference as a foundational resource for precision medicine research, real-world evidence generation, and the acceleration of drug discovery and development across a broad range of disease areas.